Results of KEYNOTE-024 trial of pembrolizumab in NSCLC
Description: Martin Reck, MD, PhD of LungenClinic Grosshansdorf, Grosshansdorf, Germany gives an overview of the KEYNOTE-024 trial results for non-small cell lung cancer (NSCLC) presented at the 2016 annual meeting of the European Society of Medical Oncology (ESMO), held in Copenhagen, Denmark. They KEYNOTE-024 trial is a Phase III trial of pembrolizumab compared to standard of care (SOC) platinum-based chemotherapies in patients with previously untreated stage IV, programmed cell death ligand 1 (PD-L1) strong expressing NSCLC (NCT02142738). The assumption was that pembrolizumab will be superior to platinum-based chemotherapies in efficacy and this was observed in the trial. The primary endpoint was progression-free survival (PFS), which was in favor of pembrolizumab with a prolongation of median PFS from 6 months to 10.3 months. There was also an improvement in overall survival (OS) as well as an improvement in response. Further, the tolerability was in favor of pembrolizumab.
Shared By : VJOncology
Posted on : 10/18/16
Added : 2 years ago